TFF Pharmaceuticals And Leidos To Advance Next-Generation Biodefense Countermeasures Under DARPA Personalized Protective Biosystems Program into Preclinical Testing
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals and Leidos are advancing next-generation biodefense countermeasures under DARPA's Personalized Protective Biosystems Program into preclinical testing. The Leidos team's medical countermeasures, formulated with TFF Pharmaceuticals' Thin Film Freezing Technology, have shown chemical and biological neutralizing activity in validated models.
May 23, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TFF Pharmaceuticals is advancing its next-generation biodefense countermeasures into preclinical testing under DARPA's program, showing promising results with its Thin Film Freezing Technology.
The advancement into preclinical testing under a DARPA program and the promising results of TFF Pharmaceuticals' technology are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100